hemotherapy-induced neuropathy.
Conditions
Interventions
Intervention 1: Intervention group: n the intervention group, there are ten sessions in each session for twenty minutes, the laser is irradiated on the lower limbs on both sides below the knees and th
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cancer patients who took the following chemotherapy drugs during treatment: 1. Platinum compounds 2. Vinca alkaloids3. Bortezomib 4. Taxans 5. Fluorouracil6. Thalidomide, lenalidomide At least 6 months have passed since the end of the patient's chemotherapy. The signs and symptoms of the disease have caused a decrease in the patient's quality of life. Filling out the Toronto questionnaire
Exclusion criteria
Exclusion criteria: Entry into the study is subject to the absence of neuropathy due to other causes of neuropathy, including diabetes, radiculopathies, hereditary and acquired neuropathies, which can be verified at the beginning of the study through history and NCV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ncreasing the score obtained in the Toronto questionnaire based on history and examination and improvement of nerve conduction. Timepoint: History and examination and nerve conduction test at the beginning of the study and two weeks after the end of laser therapy. Method of measurement: Oronto neuropathy questionnaire and nerve conduction test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholam Reza Safavi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed